RedHill Biopharma's (RDHL) Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
Go back to RedHill Biopharma's (RDHL) Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue| REDHILL BIO SP ADS (NASDAQ: RDHL) | Delayed: 0.42 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.42 | 52 Week High | $16.54 | |||
| Open | $0.42 | 52 Week Low | $8.10 | |||
| Day High | $0.42 | P/E | N/A | |||
| Day Low | $0.41 | EPS | $0.00 | |||
| Volume | 38,946 | |||||
